



12 November 2025

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

cyclopharm
medica
technegas

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Cyclopharm Completes Sale of Cyclotron Asset

Cyclopharm Limited (ASX: CYC) is pleased to advise that the sale of its non-core Cyclotron asset, previously referenced in the Company's Half-Year 2025 Results, has now been completed. Settlement has occurred and a total of \$6.2 million has been received.

As outlined in the Half-Year Results dated 27 August 2025, the transaction strengthens Cyclopharm's balance sheet and aligns with the Company's strategic focus on expanding its global Technegas® business.

Cyclopharm and Cyclotek continue to explore collaborative opportunities that leverage the complementary strengths and synergies between the two companies across radiopharmaceutical manufacturing, distribution, and clinical innovation in both domestic and international markets.

Managing Director and CEO, James McBrayer, said:

"The completion of this sale further streamlines our operations and provides additional financial flexibility to accelerate Technegas® commercial growth. Cyclotek has been a valued partner over many years, and we look forward to building on this relationship to pursue joint opportunities that enhance patient access to advanced nuclear medicine solutions."

ENDS

This ASX announcement was authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX-listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®

The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro-furnaced for a few seconds at around 2,700 °C. The resultant gas-like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology, multimodality imaging, and analytical software, is being utilised in other disease states, including COPD, asthma, pulmonary hypertension, and certain interventional applications, such as lobectomies in lung cancer and lung volume reduction surgery.